This blog has moved to Thanks for reading

Sunday, November 16, 2008

Nov 12: Pravin Chaturvedi talks: The Irrational Act of Entrepreneurship

Pravin Chaturvedi is currently the President & CSO of Napo Pharmaceuticals He has over 17 years of pharmaceutical industry experience and has been associated with the discovery and development of several novel drugs for the treatment of a variety of diseases. He is the Founder of Indus Pharmaceuticals. Prior to founding Indus, he was co-founder and was founding President & CEO of Scion Pharmaceuticals. At Scion, he successfully transformed an assay technology platform idea into an ion channel drug company. Scion is currently engaged in the discovery and development of novel, first-in-class drugs for the treatment of pain, atrial fibrillation and overactive bladder, by targeting voltage-gated ion channels. Under his leadership, Scion successfully raised approximately $30 MM in venture capital and recruited a very experienced management team that successfully achieved key scientific and business milestones.

Prior to Scion, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals, where as the Head of Lead Evaluation and he had oversight of several therapeutic programs from early discovery through clinical proof-of-concept studies (phase IIA). During his tenure at Vertex, he played a key role in the discovery and development of several therapeutic agents for immunosuppressive, anti-inflammatory, anti-viral, oncology and neuroscience indications. Prior to Vertex, Dr. Chaturvedi was in the preclinical group at Alkermes, where he participated in CNS and oncology product development through novel strategies. Prior to Alkermes, he was in the Product Development group at Parke-Davis/Warner-Lambert Company, where he worked on the development of new drugs for the treatment of oncology, epilepsy, pain and cognition. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor's in Pharmacy from the University of Bombay.

The Presentation

No comments: